Live Quote · NASDAQATOSHealthcare· Biotechnology

Atossa Therapeutics, Inc.

$2.12 3.92%(+$0.08)
TickerSpark Score
50/100
Mixed
100
Valuation
20
Profitability
15
Growth
84
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATOS research report →

52-Week Range2% of range
Low
$1.70
Current
$2.12
High
$19.35

About the company

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States.

CEO
Steven C. Quay
IPO
2012
Employees
15
HQ
Seattle, WA, US

Price Chart

-83.12% · this period
$17.70$9.72$1.75Jul 02Dec 31Jul 02
Valuation
Market Cap
$18.26M
P/E
-0.49
P/S
0.00
P/B
0.60
EV/EBITDA
0.36
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-84.91%
ROIC
-129.89%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-34,770,000 · -36.33%
EPS
$-4.04 · -34.67%
Op Income
$-37,141,000
FCF YoY
-41.50%
Performance & Tape
52W High
$19.35
52W Low
$1.70
50D MA
$4.23
200D MA
$8.11
Beta
1.25
Avg Volume
139.01K

Get TickerSpark's AI analysis on ATOS

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
May 12, 26Steinhart Richard Iother10,000
May 12, 26Chen Shu-Chihother10,000
May 12, 26Remmel H. Lawrenceother10,000
May 12, 26Finn Jonathanother10,000
May 12, 26Galli Stephen Jother10,000
May 12, 26Cigler Tessaother10,000
Mar 27, 26QUAY STEVEN Cother65,000
Mar 26, 26Daniel Mark Jamesother63,000
Jan 20, 26QUAY STEVEN Cother331,674
Jan 20, 26QUAY STEVEN Cother950,000
Coverage · ATOS

Our ATOS coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on ATOS yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate ATOS report →
Internal Compare

Similar companies

Peers in the same neighborhood.